Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)

Next Previous
Trial Profile

Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications COVID 2019 infections; COVID-19 pneumonia; Cytokine release syndrome; Respiratory insufficiency
  • Focus Registrational; Therapeutic Use
  • Acronyms RUXCOVID
  • Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

  • 14 Dec 2020 Results presented in a Novartis media release.
  • 14 Dec 2020 According to an Incyte Biosciences International media release, the data will be further analyzed to determine any potential impact on other studies of ruxolitinib in patients with COVID-19, and will be submitted for publication.
  • 14 Dec 2020 Primary endpoint has not been met. (Proportion of patients who die, develop respiratory failure [require mechanical ventilation] or require intensive care unit (ICU) care), according to an Incyte Biosciences International media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top